Rasio utang jangka dawa marang modal HUTCHMED Corp (HCM)

HUTCHMED (China) Limited (HCM) is developing a diversified oncology portfolio, expanding its presence in China and globally through alliances with corporate behemoths. Manufacturing sites adhere to environmental waste disposal standards without claiming global decarbonization. The business relies on the extensive engagement of external CRO contractors to conduct international trials, with the indicator standing at 0.06. This chart of the market price reflects the dynamics of the company's debt obligations.

For the biopharmaceutical business of HUTCHMED (China) Limited (HCM), which is focused on the expansion of fruquintinib and licensing deals, the long-term debt-to-equity ratio on GURU.Markets reflects the stability of funding for R&D cycles. This metric captures the proportion of loans with a maturity of over one year within the capital structure, where sharp spikes in the index warn of increasing financial leverage and risks should the company's operating revenues decline.